The effect of orlistat on postprandial hypertriglyceridemia by oral fat loading test. A systematic review

Efecto de orlistat sobre la hipertrigliceridemia posprandial valorada mediante el test de sobrecarga oral de grasas. Revisión sistemática

Ana Rodríguez-Valle1, María Ángeles Navarro Ferrando2, Diana Boj Carceller3, Mar González-Cantalejo4, Jesús Fernando Escanero Marcén2 and Alejandro Sanz-Paris3

1Department of Clinical Biochemistry. Hospital Universitario Miguel Servet de Zaragoza. Zaragoza, Spain. 2Universidad de Zaragoza. CIBER-OBN, IIS. Zaragoza, Spain. 3Unit of Dietetics and Nutrition and 4Biblioteca Médica. Hospital Universitario Miguel Servet. Zaragoza, Spain

Abstract

Orlistat induces weight loss by blocking hydrolysis of triglyceride in the intestine, and has thereby been associated with favorable changes in postprandial triglycerides (ppTGL). Some epidemiological studies have identified ppTGL concentrations as a significant risk factor for cardiovascular disease. Oral fat loading test (OFLT) has been used for screening of elevated levels of ppTGL. The objective of the present systematic review is to present available data on the effects of orlistat on OFLT.

We found 11 studies, seven of which studied the effect of a single dose of orlistat on OFLT in three healthy volunteers, one with obesity, two with type-2 diabetes and one with hyperlipidemic patients. The other four studied the effect of orlistat on OFLT, but after a previous period of time with daily treatment with orlistat: 1 healthy volunteer, 2 obese volunteers, and one patient with hyperlipidemia.

Our systematic review suggests that orlistat can help to reduce postprandial hypertriglyceridemia in obese, dyslipemic and type-2 diabetic patients. Regarding free fatty acids, they could be reduced but not all the authors have found the same results. In relation to type-2 diabetic patients, we have found three studies with conflicting results on the immediate effect of orlistat on the postprandial GLP-1 response.

In conclusion, orlistat can help to reduce postprandial plasmatic TGL, especially in patients with postprandial hypertriglyceridemia related to obesity, dyslipidemia or type-2 diabetes.

Resumen

Orlistat induce la pérdida de peso mediante el bloqueo de la hidrólisis de triglicéridos en el intestino, por lo que también se asocia con cambios favorables en los triglicéridos posprandiales (PHTGL). Algunos estudios epidemiológicos han identificado concentraciones PHTGL como un importante factor de riesgo para la enfermedad cardiovascular. El test de sobrecarga oral de grasa (TSOG) se ha utilizado para la detección de niveles elevados de PHTGL. El objetivo de la presente revisión sistemática es presentar los datos disponibles sobre los efectos de orlistat en TSOG.

Encontramos 11 estudios, de los cuales 7 estudian el efecto de una sola dosis de orlistat en el TSOG: 3 con voluntarios sanos, 1 con obesidad, 2 con diabetes de tipo 2 y 1 con pacientes hiperlipidémicos. Los otros 4 estudian también el efecto de orlistat en el TSOG, pero después de un período de tiempo previo con un tratamiento diario con orlistat: 1 voluntario sano, 2 obesos y 1 paciente con hiperlipidemia.

Nuestra revisión sistemática sugiere que orlistat puede ayudar a reducir la hipertrigliceridemia posprandial en pacientes obesos, dislipídicos y con diabetes de tipo 2. Respecto a los ácidos grasos libres plasmáticos, también los podría reducir, pero no todos los autores han encontrado los mismos resultados. En pacientes diabéticos de tipo 2 se han encontrado tres estudios con resultados contradictorios sobre el efecto inmediato de orlistat en la respuesta postprandial de GLP-1.

En conclusión, orlistat puede ayudar a reducir los TGL plasmáticos posprandiales, especialmente en pacientes con hipertrigliceridemia posprandial relacionada con obesidad, dislipidemia y diabetes de tipo 2.
INTRODUCTION

Humans consume regular meals during the day; therefore, we are in a dynamic state of continuous changes in postprandial lipid and lipoprotein metabolism. Postprandial lipemia is a normal physiological phenomenon that usually lasts from 6 to 8 hours after ingestion of a fatty meal. However, postprandial hypertriglyceridemia (PHTGL) is an exaggerated magnitude and duration of triglyceride (TGL) response after a fatty meal, which results in the accumulation of TGL and their remnants in the circulation.

The causes of PHTGL include: decreased hepatic receptor activity, defect in the ligand for these receptors, impaired lipolysis by lipoprotein lipase (LPL) and Apo C (Apolipoprotein C) dysregulation by acting as an inhibitor of LPL and TGL remnant uptake by hepatic lipoprotein receptors (1).

The atherogenicity of TGL relates to the smaller remnant particles that readily infiltrate the subendothelial space of the arterial wall. These TGL remnants are phagocytized by arterial wall macrophages, which then transform into foam cells, impair endothelial function, activate monocytes and inflammatory signaling pathways, and also have a direct effect on thrombogenicity (2,3).

Some epidemiological studies have identified non-fasting TGL concentrations as a significant risk factor for cardiovascular disease. Copenhagen City Heart study (4), Women’s Health study (5) and the Norwegian Counties study (6), all found highly significant associations between cardiovascular events with increases in non-fasting TGL.

Furthermore, the findings in the 31st year follow-up of Copenhagen City Heart study (4) were in agreement with its previous data, with non-fasting TGL being similarly associated with an increased risk of myocardial infarction, ischemic heart disease (7), and ischemic stroke (8). In addition, there is a meta-analysis of 101 studies suggesting the causal role of plasma TGL in coronary disease (9).

The role of TGL has been emphasized by recent major guidelines. A therapeutic fasting target level of triglyceride of less than 150 mg/dL is recommended in higher-risk patients, especially those with diabetes and metabolic syndrome (10,11).

Non-fasting TGL cutoff levels of ≥ 180 mg/dL and > 220 mg/dl after the Oral Fat Loading Test (OFLT) have been used for screening and management of elevated TGL levels (12).

Dietary and lifestyle modifications remain the cornerstone of therapeutic management, whose function is to lower plasmatic TGL, and this is the first-step approach. Subsequent steps are pharmacotherapies including fibrates, niacin (currently not available in Spain), and n-3 fatty acids.

New therapies, such as dual peroxisome-proliferator-activated receptor α/δ agonists, diacylglycerol, inhibitors of diacylglycerol acyltransferases-1, microsomal triglyceride transfer protein, antisense oligonucleotides for apob-100 and apoc-III, and incretin-based therapies could be employed to optimize the treatment.

Orlistat is a drug approved in the year 1999 for long-term weight loss in adults. Orlistat induces weight loss by blocking the hydrolysis of triglyceride in the stomach and small intestine, thereby, inhibiting absorption of approximately 30% of dietary fat.

Anti-obesity drugs help to reduce body weight, thus, contributing to an improvement in cardiovascular risk factors. However, the direct effect of anti-obesity drugs on cardiovascular risk factors is unclear (13). Orlistat not only induced weight loss, but it was also associated with favorable changes in lipids, fasting glucose, and blood pressure. The Orlistat Swedish Multi-morbidity Study showed greater improvement in coronary risk factors with orlistat than with diet changes alone in obese patients with hypertension, hypercholesterolemia, and/or type 2 diabetes (14). These results have been observed in other studies (15). More so, the metabolic effects of orlistat are not only limited to cardiovascular risk factors, but also to a lower incidence of type 2 diabetes (16).

Orlistat may represent a pharmacological approach to cardiovascular risk modulation in overweight/obese patients, although no agency has admitted that indication. The objective of the ongoing systematic review is to present available data on the effects of orlistat on OFLT.

METHODS

SEARCH STRATEGY

A literature search has been made in the following medical databases through June 2015: Medline (PubMed), Embase, Cochrane Library and Trip Database. National and international agencies like the CRD (Centre for Reviews and Dissemination), NICE (National Institute for Health and Care Excellence), HEN (Health Evidence Network), IQWIG (Institute for Quality and Efficiency in Health Care), INAIHTA (International Network of Agencies for Health Technology Assessment), EuroScan, NHSC (NIHR Horizon Scanning Centre), AHRQ (Agency for Healthcare Research and Quality), CEDIT (Comité d’évaluation des technologies de santé), CADTH (Canadian Agency for Drugs and Technologies in Health), UKMI (United Kingdom Medicines Information, NHS), EMEA (European Medicines Agency), AEMPS (Spanish Agency for Medicines and Health Products), AETS-ISCIII (Agency for Health Technology Assessment of the Institute Carlos III, Spain), OSTEBA (Service Health Technology Assessment of the Basque Country), AETSA (Agency for Health Technology Assessment Andalusia) were also revised.

The literature search in medical databases followed these steps:

1. “Hyperlipidemias” [mesh] and “Postprandial period” [mesh].
3. #1 OR #2.
4. “Orlistat” [supplementary concept].
5. Xenical [title/abstract] OR orlistat [title/abstract].
6. #4 OR #5.
7 #3 AND #6.
A filter for studies in humans was also used. The search was restricted to articles in English and Spanish languages. The search was refined by eliminating duplicate documents.

The retrieved studies were manually screened to assess their appropriateness for inclusion. Bibliographies of all identified trials and review articles were reviewed to look for additional studies of interest.

An investigator reviewed all the citations retrieved from the electronic search in order to identify relevant articles for this review. Other investigators subsequently reviewed the selection, to determine eligibility.

INCLUSION AND EXCLUSION CRITERIA

Inclusion criteria: Studies with healthy, cardiovascular or metabolic disease participants, regardless of their body mass index (BMI), their age (> 18 years), with no chronic medication, who underwent an OFLT were included.

Exclusion criteria: Reports, editorials and review articles were excluded.

DATA EXTRACTION AND QUALITY EVALUATION

All articles provided measures for blood determinations, including mean and standard deviation (SD) or standard error of the mean (SEM), at least at baseline and at one other postprandial time point. The following data were abstracted in tables onto the standardized case report forms: authors; year of publication; number of patients, sex, age, BMI and characteristics of the treatment and control groups (healthy, obese, hyperlipidemia, metabolic syndrome or diabetes); study goals; methods of randomization and blinding; duration and characteristics of treatment; administered fat load test; outcomes; and adverse event data.

A validated 3-item scale was used to assess the overall reporting quality of the selected studies for inclusion in the present review (17). This scale provides scoring for randomization (0-2 points), double-blinding (0-2 points), and account for withdrawals (1 point). Scores ranged between 0 and 5, and scores ≥ 3 indicate a high quality study.

RESULTS

A total of 78 citations were identified by the systematic literature search (66 from medical databases and 12 from national and international agencies), 49 of which were deemed potentially eligible. 38 of the 49 articles were excluded because they did not meet the inclusion criteria. Thus, a total of 11 trials were eligible for analysis (18-28), only 7 of which were double-blind randomized controlled trials (RCT) (18,19,22-26) (Fig. 1).

A total of 7 papers (18-24) studied the effect of a single dose of orlistat on OFLT (Table I), 3 of which were carried out with healthy volunteers (18-20), 1 with obese patients (21), 2 with type 2 diabetes patients (22,23), and 1 with hyperlipidemic patients (24).

Of the total 11 included studies, only 4 studied the effect of orlistat on postprandial lipemia, after a period of time with a daily treatment using orlistat (24-28) (Table I). Among these, 1 was carried out with healthy volunteers (25), 2 with obese (26,27), and 1 with hyperlipidemic patients (24).

Only one study conducted an OFLT after 8 weeks of orlistat treatment and a second OFLT after two weeks of placebo (24), so it is included in all tables.

STUDY CHARACTERISTICS

The characteristics of the included studies are listed in tables I and II, and summarized in tables III and IV.

There are two studies that are not randomized or blinded (20,21), but they were included due to the number of patients. The dose of fat used in the OFLT was variable, with about
**Table I. Characteristics of studies with single dose of orlistat**

<table>
<thead>
<tr>
<th>Author</th>
<th>Patients</th>
<th>Methodology</th>
<th>Orlistat administration</th>
<th>Results with orlistat</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sutter (18)</td>
<td>10 healthy young men BMI 21.5 ± 1.2 kg/m² Age 25 ± 3 years</td>
<td>Double-blind, randomized, crossover study. Postprandial TGL 8 h AUC was determined on 3 separate days. Each test meal contained either 1 g (high fat) or 0.67 g (moderate-fat) of fat per kg body weight</td>
<td>Single-dose orlistat 120 mg plus a high-fat meal or moderate fat meal, or placebo plus high fat meal</td>
<td>Orlistat leads to: 1. Lower postprandial TGL response and significant reduction in the AUC-TGL 2. VLDL size was significantly smaller 3. Decrease in small HDL particle concentration and increase in intermediate HDL</td>
</tr>
<tr>
<td>Gabriel (19)</td>
<td>31 healthy volunteers BMI 18.5-23.5 Age range of 18 to 45 years Male and female Normal fasting lipids</td>
<td>Blingly randomized study High fat meal: 50% fat meals Lipid level determination at 0, 4, 5 and 9 h</td>
<td>Receive either placebo or orlistat 120 mg before each main meal during one day</td>
<td>TGL, VLDL; LDL and TC for orlistat group was lower than placebo group</td>
</tr>
<tr>
<td>Abejuela (20)</td>
<td>27 healthy volunteers BMI 18.5-22.9 kg/m² Age range of 18-45 years Normal fasting lipid levels</td>
<td>No blindly randomized study 50% oral fat challenge test Plasma lipid was determined at 0, 1, 2, 3, 4, 5 and 6 h</td>
<td>15 volunteers receive orlistat 120 mg and 12 volunteers none before oral fat challenge test</td>
<td>Lipid peaking was not observed in the orlistat group</td>
</tr>
<tr>
<td>Cintora (21)</td>
<td>33 overweight/obese patients BMI: 31.4 ± 4.4 Age: 44.3 ± 9.9 years</td>
<td>No blindly randomized study 50% oral fat challenge test Plasma lipid was determined at 0, 1, 2, 3, 4, 5 and 6 h</td>
<td>Two-days study: standardized, fat-containing meal on day 1 and the same meal plus a single oral dose of orlistat (120 mg) on day 2</td>
<td>The addition of orlistat reduced: 1-the value peak plasma concentration of TG (at 4 h but not at 8am) 2-TGL-AUC by 54.9%</td>
</tr>
<tr>
<td>Tan (22)</td>
<td>63 overweight patients with T2DM BMI: 30.4 ± 3.8 Age: 45.2 ± 10.7</td>
<td>Randomized, double blind, placebo-controlled cross-over study The test meal contained 70 g of fat Blood samples were collected at baseline before the test meal and then at 2 h intervals for 8 h</td>
<td>Either a single dose of orlistat 120 mg or placebo was given before a standard mixed meal</td>
<td>The concentrations of plasma TGL, RLP-C, and FFA were significantly lower at 2 h after orlistat compared with placebo</td>
</tr>
<tr>
<td>Damci (23)</td>
<td>29 T2DM patients, who were not taking insulin or alpha glucosidase inhibitors BMI: 31.0 ± 4.1 Age: 54.9 ± 10.4 years</td>
<td>Crossover randomized and single-blind design At baseline and 60 min after the meal, blood samples were obtained Standard 600-kcal mixed meal that contained 38% fat (25 g)</td>
<td>A single dose 120 mg orlistat or placebo capsules</td>
<td>The orlistat administration enhanced postprandial increase in GLP-1 and C-peptide levels and attenuated the postprandial rise in glucose and TGL</td>
</tr>
<tr>
<td>Reitsma (24)</td>
<td>17 hyperlipidemic subjects: fasting plasma CT &gt; 6.2 mmol/l and TGL &gt; 5 mmol/l BMI: 24.8 ± 3.4 kg/m² Age: 55.0 ± 2 6.9</td>
<td>Multicenter double-blind, randomized Test meal: 50 g fat/m² on the last day of 8 weeks treatment period and after 2 weeks placebo period Peripheral blood samples: before and at 2-hour intervals after test meal</td>
<td>First oral load test: placebo or orlistat doses from 8 weeks treatment period Second oral load test: a single dose of orlistat 120 mg or placebo after 2-week follow-up period on placebo (weeks 8 to 10)</td>
<td>Reductions of TC, LDL, and apo B levels with 8 weeks orlistat treatment Postprandial TGL was decreased by 27% Changes in the TGL AUC were associated with changes in the RP AUC and decreased levels in LDL cholesterol</td>
</tr>
</tbody>
</table>

**B**mi: Body mass index; **tC**: Total cholesterol; **TGL**: Triglyceride; **LDL**: Low density lipoproteins; **HDL**: High density lipoproteins; **VLDL**: Very low density lipoproteins, retinyl palmitate (RP); **AUC**: Area under the curve; **T2DM**: Type 2 diabetes mellitus; **RLP-C**: Remnant-like particles cholesterol; **GLP-1**: Glucagon-like peptide 1.
28 grams (25) to 60 grams per square meter of body surface (27). In many studies, the exact dose of fat used is not clearly defined. In this regard, studies are not comparable. However, the dose of Orlistat used was always 120 mg, as a single dose or in short treatment (before breakfast, lunch and dinner). In most studies, TGL area under the curve (AUC) was calculated. Meta-analysis was not considered because test meals, duration of observation in the postprandial state, and the type of patients differ within the study.

### Table II. Characteristics of studies after sort treatment of orlistat

<table>
<thead>
<tr>
<th>Author</th>
<th>Patients</th>
<th>Methodology</th>
<th>Orlistat administration</th>
<th>Results with orlistat</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shepard (25)</td>
<td>24 healthy male in placebo group:</td>
<td>Double-blind, randomized, parallel group, placebo-</td>
<td>Orlistat 120 mg or placebo three times per day during 10 days</td>
<td>There were no treatment differences in peak TGL response and AUC for any of the postprandial lipids or lipoproteins, including TGL, LDL and VLDL The inhibitory effect of orlistat on lipase is limited to the gastrointestinal tract and is not manifested systemically</td>
</tr>
<tr>
<td></td>
<td>Age: 31 ± 2 y BMI: 25.1 ± 0.5</td>
<td>controlled study Fat rich breakfast (830 Kcal and 28 g fat) and single dose of orlistat or placebo Determinations were made prior to breakfast and then hourly over 12 h, in day 0 and days 5 and 10</td>
<td>Meal test plus single dose of orlistat or placebo on days 5 and 10 was performed</td>
<td></td>
</tr>
<tr>
<td></td>
<td>In orlistat group:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Age: 35 ± 2 years BMI: 26.8 ± 1.0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Di Somma (26)</td>
<td>22 healthy postmenopausal women with obesity class I-II BMI: 34.1 ± 4.0 Age: 53.6 ± 6.2</td>
<td>Randomized, simple-blind, cross-over study At the end of 10 day treatment period was performed postprandial test. Determinations at 0, 2, 4, 6 and 8 h. Meal provided 944 Kcal and 57% fat Standard mixed meal (944 Kcal and 60 g fat)</td>
<td>120 mg after meals or placebo during 10 days plus normocaloric diet</td>
<td>Orlistat induced a weight independent reduction in postprandial NEFA associated with an improvement in GH/IGF-I status</td>
</tr>
<tr>
<td>Turker (27)</td>
<td>26 normolipemic obese female with PPL</td>
<td>Prospective, randomized, no blind study A meal contained 60 g/m2 fat and 1,800 Kcal with 64% of total calories from fat Determination of serum lipids 0,2,4,6 and 8 h</td>
<td>One group with diet and orlistat 120 mg 3 times/day and other group only diet, during 12 weeks</td>
<td>Reduction in TGL Related to fasting TGL, insulin and HOMA at 12 weeks</td>
</tr>
<tr>
<td>Tzotzas (28)</td>
<td>32 obese, non-diabetic women with metabolic syndrome Age: 50.1 ± 8.2 years</td>
<td>Prospective, randomized, no blind study Capillary triglycerides (TGc) were measured at 6 different time points during the day Daytime triglyceridemia was expressed as area under the curve of TGc (AUC-TGc) Low-calorie diet: 1,480 ± 45 kcal/day Fat 29.5%</td>
<td>2 similar groups: G1 with a low-calorie diet combined with orlistat 120 mg tid for 10 days and G2 (control), with only the low-calorie diet</td>
<td>Following minimal weight loss, AUC capillary TGL decreased by 17%. It was significantly correlated with the decrease of HOMA index</td>
</tr>
</tbody>
</table>

### HEALTHY VOLUNTEERS

We found that 3 studies were done with a single dose of orlistat in healthy volunteers (18-20), which make up 68 individuals in all. The response to the OFLT was homogeneous in all patients with a reduced postprandial triglyceride AUC compared to placebo. In addition, a significant reduction of total LDL cholesterol levels (19,20), HDL cholesterol (18,20) and VLDL (18,19) was observed.
Regarding the response of postprandial free fatty acids (FFA), glucose and insulin, only one study explored this (18), with no significant results.

After 10 days of treatment with orlistat, Shepard et al. (25), in an article of high methodological quality, found no significant difference regarding the postprandial response with orlistat compared to placebo in any of the previously mentioned parameters.

### NORMOLIPEMIC OBESE POST MENOPAUSE FEMALE

We have found only two articles with normolipemic obese post menopause female.

Cintora et al. (21) conducted an OFLT with orlistat and observed an attenuation of the AUC and peak of TGL at 4 hours.

Later, Di Somma et al. (26) performed an OFLT after 10 days of daily treatment with orlistat. The result showed lower postprandial response in the treatment group in total cholesterol, LDL cholesterol, HDL cholesterol, FFA and insulin, but not in TGL.

### DISLIPEMIA

We have found three papers with different types of dyslipidemia: obese with only PPL (27), obese with metabolic syndrome (28) and obese with fasting hyperlipidemia (24). In all three studies, the authors observed a decreased response of TGL after the OFLT with orlistat. The reduction of TGL was significantly correlated with decreased fasting TGL, insulin and HOMA after 12 weeks or after 10 days of orlistat treatment.

### TYPE 2 DIABETES MELLITUS

In two studies (22,23) TGL lower postprandial response is observed with administration of orlistat. Postprandial FFA response

### Table III. Summary of results of single dose of orlistat studies

<table>
<thead>
<tr>
<th>Author</th>
<th>Patients, fats, Jadad score</th>
<th>TGL</th>
<th>FFA</th>
<th>VLDL</th>
<th>HDL</th>
<th>LDL</th>
<th>TC</th>
<th>RLP-C</th>
<th>Glucose</th>
<th>Insulin</th>
<th>C-Peptide</th>
<th>GLP-1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sutter (18)</td>
<td>10 healthy OFLT fats: 1 vs. 0.67g/kg Jadad score: 4</td>
<td>Shorter Reduction AUC</td>
<td>ns</td>
<td>Smaller Smaller decrease in small HDL Smaller increase in intermediate HDL</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>ns</td>
<td>ns</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Gabriel (19)</td>
<td>31 healthy OFLT Fats: 50% Jadad score: 3</td>
<td>Lower Lower ns Lower Lower</td>
<td>-</td>
<td>Lower</td>
<td>Lower</td>
<td>Lower</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Abejuela (20)</td>
<td>27 healthy OFLT fats: 50% Jadad score: 0</td>
<td>Lower Lower Lower Lower Lower</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Cintora (21)</td>
<td>33 overweight obese, OFLT fats: 53 g Jadad score: 0</td>
<td>Attenuated AUC and peak at 4 h</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Tan (22)</td>
<td>63 T2DM OFLT fats: 70 g Jadad score: 4</td>
<td>Lower at 2 h Lower at 2 h</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>ns</td>
<td>Lower Lower AUC</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Damci (23)</td>
<td>29 T2DM OFLT fats: 25 g Jadad score: 3</td>
<td>Attenuated Attenuated</td>
<td>ns</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>Attenuated ns Enhanced Enhanced</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reitsma (24)</td>
<td>17 hyperlipidemic OFLT fats: 50 g/m² Jadad score: 4</td>
<td>Attenuated Attenuated</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

TC: Total cholesterol, TGL: Triglyceride, LDL: Low density lipoproteins, HDL: High density lipoproteins, VLDL: Very low density lipoproteins, RLP-C: Remnant like particles cholesterol, AUC: Area under the curve, OFLT: Oral fat loading test, T2DM: Diabetes mellitus type 2, Jadad score (17).
in a paper is lower (22) whereas in the other it is not significant (23). Tan et al. (22) describe lower peak and AUC of remnant like particles cholesterol. Damci et al. (23) showed attenuated glucose response with enhanced C-peptide and GLP-1 response.

**DISCUSSION**

Orlistat is a synthetic hydrogenated derivative of lipstatin that partially inhibits gastric lipase, pancreatic lipase and carboxyl ester lipase enzymes. It reduces the absorption of ingested fat by 30%, increasing its excretion in the feces.

The European Medicines Agency (29) and the American FDA (30) approved its use only as a prescription agent for long-term weight loss in adults with a BMI > 30 kg/m² or a BMI > 27 kg/m², with comorbidities and in conjunction with a reduced-calorie diet.

Therefore, orlistat could improve lipid metabolism, ameliorating postprandial TGL increase and fasting LDL cholesterol levels. Thus, orlistat may represent another relatively unexplored pharmacological approach to cardiovascular risk pathologies (31).

**EFFECT ON TRIGLYCERIDES**

Our systematic review suggests that orlistat can help to reduce PHTGL in obese, dislipemic and type 2 diabetic patients. In our revision, we have identified nine out of a total of eleven studies where orlistat attenuates postprandial TGL response to an OFLT. Only two studies (25,26) did not find significant results. One possible reason could be that individuals studied were normolipemic, so the increase after OFLT was too small to detect statistical significant differences. Furthermore, in these two studies orlistat treatment was prescribed before the OFLT (during ten days) and this could have attenuated the effect.

PHTGL may contribute to the increased risk of cardiovascular disease since there is evidence that accumulation of the remnant particles is highly atherogenic (2,3). In addition, there is a weight-independent reduction in LDL-cholesterol in patients using orlistat, and it could be a good alternative for patients that do not tolerate statins (32). Hutton and Fergusson (33) reviewed 28 RCTs comparing orlistat to placebo during 6 months. The data showed a significant decrease in total cholesterol and LDL cholesterol with smaller decreases in serum TGL and HDL cholesterol.

Reitsma et al. (24) presented the first study about the effect of orlistat on OFLT, and speculated that the minor absorption of dietary fat with orlistat leads to a decreased formation of chylomicrons and chylomicron-remnants. The reason for the underlying mechanism could be that they are removed from circulation by the liver using the LDL receptor. Reduction in dietary fat absorption by orlistat may decrease the flux of cholesterol and TGL particles in the liver, resulting in the upregulation of hepatic LDL (34). Chylomicron-remnants are rich in cholesterol but poor in TGL, and that means a possible role in the process of atherogenesis.
Later, others authors (18–20) showed similar results in healthy volunteers. They studied other steps of the TGL metabolism. Suter et al. (18) evaluated the effect of orlistat on postprandial lipemia and lipoprotein particle subclass after the ingestion of moderate and high-fat meals in healthy volunteers. Mean change in large VLDL subclass concentration and mean VLDL size were significantly lower with orlistat. Large VLDL particles are preferentially metabolized to small, dense LDL particles which may have an increased atherosclerotic potential (37). But Suter et al. (18) were not able to discriminate between intestinal chylomicrons and hepatic VLDL. In two studies with Philippine healthy volunteers (19,20), orlistat abolished postprandial peak of TGL and VLDL after a single high-fat meal.

In a study with type 2 diabetic patients, Tan et al. (22) discovered a significant acute effect of a single dose of orlistat on remnant-like particles of cholesterol. PHTGL is an inherent feature of diabetic dyslipidemia, and is frequently found even in diabetic patients with normal fasting triglyceride due to the long residence time of chylomicron and VLDL remnants in circulation (38). Triglyceride-rich lipoprotein remnants are formed by lipoprotein lipase from intestinal chylomicrons in smaller and denser particles. These remnant particles are enriched in cholestereryl esters and poor in TGL. Some studies had shown that post-prandial changes in small remnant particles contribute to the severity of coronary heart disease in patients with type 2 diabetes mellitus (39,40).

**EFFECT ON FREE FATTY ACIDS (FFA)**

Tan et al. (22) also found a significant reduction in plasma FFA in patients with type 2 diabetes after treatment with orlistat which had not been previously reported. Di Somma et al. (26) observed the same results in obese patients with metabolic syndrome, but Sutter et al. (18), in healthy volunteers, and Damci et al. (23) did not find significant differences in type 2 diabetic patients.

Plasma FFA concentrations normally decrease in the early post-prandial period as the release of FFA from adipose tissue is suppressed by insulin and FFA derived from lipolysis of intestinal triglyceride-rich lipoproteins are taken up by the liver and re-esterified into triglyceride. Patients with type 2 diabetes have higher fasting and postprandial FFA (41). Orlistat could reduce FFA possibly by the decreased formation of chylomicrons, but not all authors have found the same results.

**EFFECT ON GLUCAGON-LIKE PEPTIDE-1 (GLP-1)**

In obese type 2 diabetic patients, orlistat treatment is associated with improved glycemic control in the long term (42) and also with a lower incidence of type 2 diabetes in individuals with prediabetes (16). The anti-hyperglycemic effect of orlistat has been attributed to weight loss associated with a decrease in insulin resistance. However, the improvement in postprandial glucose levels with orlistat could be related to the improvement of postprandial secretion of certain incretins, such as GLP-1, due to increased delivery of fats to the distal ileum. An increase of GLP-1 mediated by orlistat could lead to suppressed appetite and improvement in meal-stimulated insulin release.

However, in type 2 diabetic patients we have found three studies with conflicting results over the immediate effect of orlistat on the postprandial GLP-1 response. Damci et al. (23) found that a single dose of orlistat significantly enhanced the postprandial increase in GLP-1 and C-peptide levels and attenuated the postprandial rise in glucose and triglycerides in 29 type 2 diabetic patients.

Pillichiewicz et al. (43) studied, in 7 subjects with type 2 diabetes mellitus, the effect of adding orlistat to a liquid meal containing oil and glucose consumed in the left lateral decubitus position. They found that orlistat potentiates postprandial rises in plasma insulin but attenuates plasma GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) responses. Later, the same group presented another study with 8 type 2 diabetic patients (44), and they once more discovered that the inhibition of fat absorption by orlistat results in a more rapid gastric emptying and a diminished GLP-1 response.

The same group of healthy volunteers (45) showed that the increase in GLP-1 concentrations following a duodenal fat infusion is abolished by lipase inhibition with orlistat.

Sahin et al. (46) found in 16 obese non-diabetic patients that orlistat had no significant effect on postprandial GLP-1, glucose or insulin levels after a mixed meal, although GLP-1 and insulin peaks were delayed into the second postprandial hour after treatment with orlistat.

These contradictions regarding results could be explained by various factors like short life of plasma insulin or GLP-1, different type of hypoglycemic treatments or amount of fat in the OFLT. Furthermore, Beyson et al. (47) demonstrated differential stimulation of GLP-1 release by different types of oral fat (monounsaturated, olive oil; polyunsaturated, safflower oil; saturated, palm stearin). The failure to get this effect with statistical significance may be due to the fact that there was only a single postprandial sampling of blood in these studies (23,43-46).

In a repetitive administration of orlistat over a 10 day period, Di Somma et al. (26) found lower postprandial levels of plasmatic insulin in OFLT with orlistat, but they did not study GLP-1 levels. In our opinion, the results of Damci et al. (23) are more convincing because plasma half-life of C-peptide is 30 minutes, whereas insulin half-life is about 5 minutes.

**EFFECT ON GASTRIC EMPTYING**

On the other hand, orlistat has been reported to induce accelerated gastric emptying of fat and glucose, as O’Donovan studies (43-45) and other groups have demonstrated (48,49). Moreover, the lack of pancreatic lipase activity in cystic fibrosis with exocrine insufficiency results in an acceleration of gastric emptying due to a reduction in feedback inhibition from lipolytic products in the small intestine (50). Gastric emptying accounts for approximately 35% of the variance in initial postprandial blood glucose concentrations after a 75 g oral glucose load in both healthy subjects (51) and type 2 diabetes (52).
EFFECT ON FASTING NORMOLIPEMIA AND PHTGL PATIENTS

There are patients with fasting normolipemia and PHTGL. Its prevalence has not been established but it is associated with metabolic syndrome components, like androgen obesity, dyslipemia and insulin resistance. This kind of patients could represent the main target of therapy with orlistat. Turk et al. (27) found, in fasting normolipidemic obese women and PHTGL, that 12 weeks of treatment with orlistat plus a low calories diet was associated with a reduction in postprandial TGL, independent of reductions from baseline in weight, waist circumference and insulin resistance.

The prescription label of orlistat establishes that the pharmacologic effect of the drug is observed within 24–48 hours based on the amount of fecal fat excreted (35,36). We have identified in this systematic review 7 papers (18,24) that studied the acute effect of a single dose of orlistat on OFLT. It is important to note this fast effect because it is an expensive treatment and this test could select the responders’ patients. OFLT is a test that examines responses to high-fat meal consumption (53) and it is indicated to diagnose PHTGL, in the same way that an oral glucose tolerance test is used for diabetes diagnosis. The association of orlistat to OFLT could offer double interest: diagnosis of PHTGL and orlistat potency in each patient.

Our present review presents several methodological limitations because of the heterogeneity of the studies. The absence of standardization of OFLT is the most important problem regarding its general use. Castro-Cabezas et al. (54) have proposed the autodetermination of diurnal capillary TGL after each meal. Moreover, non-fasting TGL has been used for screening and management of elevated levels of TGL in recent major guidelines (10,11). Secondly, the majority of the study presents a very small number of patients, so their results can only suggest tendencies. Thirdly, there is a very low number of studies for each group of patients, which are joined to the small number of patients in each study, making it impossible to perform a meta-analysis.

CONCLUSION

Despite these limitations, we can conclude that the positive and consistent findings of the included studies suggest that orlistat can help to reduce postprandial plasmatic triglyceride, especially in patients with postprandial hypertriglyceridemia related to obesity, dyslipidemia or type-2 diabetes.

REFERENCES

A SYSTEMATIC REVIEW

THE EFFECT OF ORLISTAT ON POSTPRANDIAL HYPERTRIGLYCERIDEMIA BY ORAL FAT LOADING TEST.


29. Agencia Española de Medicamentos y Productos Sanitarios AEMPS. Nota informativa de la reunión del Comité de Medicamentos de uso Humano (CMH), celebrada el 11 de marzo de 2014.


